Neurocrine Biosciences announced on Apr. 6 that it will acquire Soleno Therapeutics for $2.9 billion, a move that expands Neurocrine’s presence in endocrinology and rare diseases.
The acquisition is significant as it strengthens Neurocrine's commercial portfolio and marks its entry into the market for treatments targeting Prader-Willi syndrome (PWS), a rare genetic disorder characterized by extreme hunger leading to obesity. The boards of both companies have approved the deal, which is expected to close within 90 days pending customary conditions.
Under the agreement, Neurocrine will purchase all outstanding shares of Soleno at $53 each, representing a 51% premium over Soleno’s average trading price during the past month. Analysts at RBC Capital Markets said the acquisition "makes very reasonable strategic sense," citing potential synergies between Neurocrine's existing salesforce and Soleno’s capabilities in pediatric endocrinology.
However, analysts at Stifel described the deal as "surprising" from Soleno’s perspective despite acknowledging that mergers and acquisitions are generally positive. They wrote to investors, "While M&A is never a bad thing . . . we’d admittedly surprised SLNO sold at this price," expressing optimism about Vykat XR—the company’s only product—which was approved in March 2025 for treating hyperphagia in PWS patients.
Vykat XR is notable as the first therapy specifically approved by the Food and Drug Administration for hyperphagia in PWS. In less than a year on the market, more than 1,200 patients began treatment with Vykat XR, generating $190 million in sales. BMO Capital Markets forecasted future annual sales could reach $450 million this year and surpass $2 billion worldwide by the mid-2030s if Neurocrine successfully accelerates commercial efforts.
Following completion of this transaction, Vykat XR will become Neurocrine's third marketed product alongside Ingrezza—approved for tardive dyskinesia—and Crenessity—approved for classic congenital adrenal hyperplasia.
